How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.

ABSTRACT:

Background

Endometrial cancer (EC) represents the sixth most common female tumor. In the advanced setting, the prognosis is dismal with limited treatment options. Platinum-based chemotherapy represents the actual standard of care in first-line chemotherapy, but no standard second-line chemotherapy is approved, with less than 1/4 of patients responding to second-line chemotherapy. In the last 10 years, immune checkpoint inhibitors (ICIs) have changed the treatment landscape of many solid tumors.

Methods

The review was conducted according to the PRISMA guidelines. We searched EMBASE, MEDLINE, Cochrane Database, and conference abstracts from international societies, up to November 2021. Clinical trials employing ICIs in advanced EC, written in English, were included. Reviews, l

SUBMITTER: Maiorano BA 

PROVIDER: S-EPMC9047829 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature